Published in Lab Business Week, June 13th, 2004
Revenues for the first quarter of 2004, which relate entirely to discontinued operations, were $1.0 million compared to $3.3 million for the same quarter in 2003, also entirely from discontinued operations. The first quarter 2003 revenues are after exceptional charges of $6.1 million relating to Permax inventories and deductions.
During the first quarter of 2004 and as previously reported, Amarin sold the majority of its U.S. operations to Valeant Pharmaceuticals International. This sale, which resulted in a loss in the quarter of $2.4 million, comprised...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week